Videos

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Key opinion leaders describe the role of blood-based MRD testing in the transplant-ineligible multiple myeloma treatment landscape.

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

Stacy A. Cohen, MD and Mark Lewis, MD share key takeaways from the GALAXY study and discuss the clinical implications of using ctDNA-based assays for patients with CRC.

Experts describe cumulative ctDNA clearance rates in patients with stage I-IV disease who did or did not receive adjuvant chemotherapy in the GALAXY study.

Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

Alina Markova, MD, highlights the safety and tolerability of topical ruxolitinib INCB018424 phosphate 1.5% cream for patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Experts review a second patient case wherein transplant-ineligible newly diagnosed multiple myeloma was treated with the daratumumab, lenalidomide and dexamethasone regimen and how updated data from the MAIA trial can be incorporated into clinical practice.

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Considerations for assessing eligibility of patients for transplantation for NDMM and how maintenance therapy may be initiated in the post-transplant setting.

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

Uday R. Popat, MD, spoke about how use of post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease following matched donor hematopoietic cell transplantation for acute myeloid leukemia could impact the standard of care.

A look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.

Experts have a conversation of the use of trastuzumab deruxtecan therapy for patients with progressive brain metastases while weighing common toxicities and clinical trial data.

Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.

The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.

Program chair Navel Daver, MD, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.

Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.

Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.

Stacy A. Cohen, MD, and Mark Lewis, MD, discuss how DFS correlates with stage and adjuvant chemotherapy receipt in patients who are ctDNA-positive.

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.

GI oncologists discuss DFS data from the dynamics analysis cohort of the GALAXY study.